본문 바로가기
KERD
논문KCI 등재

Long COVID의 주요 증상에 대한 한의학적 고찰과 치료 제안

Korean Medicine Review and Treatment Suggestions for the Main Symptoms of Long COVID

이은아|김형우|황요순
한의병리학회 (The Society of Pathology in Korean Medicine)|2022.10|동의생리병리학회지 (Journal of Physiology & Pathology in Korean Medicine)|제36권 제5호|pp. 155-162

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

COVID-19Herbal medicineKorean medicineLong COVIDPost-COVID conditions
주제분류한의학

초록

Even after testing negative for COVID-19, some patients continue to struggle with a variety of symptoms such as fatigue, shortness of breath, gastrointestinal problems and neurological problems. The World Health Organization (WHO) defined long COVID (Post COVID-19 conditions) as “A disease occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months, that cannot be explained by an alternative diagnosis.” As a possible pathological mechanism of long COVID, three hypotheses are proposed: the persistence of the infectious state due to the residual virus, the persistent inflammatory response, and the autoimmune response. The main symptoms of long COVID are shortness of breath (dyspnea), abdominal pain and dyspepsia, fatigue, cognitive problems (brain fog), anosmia and dysgeusia, and chest pain, palpitations and tachycardia. In the Chinese guidelines, COVID-19 patients were divided into mild, moderate, severe, and recovery, and prescriptions with effective therapeutic effects were summarized to encourage combined treatment of chinese and western medicine. Globally, only symptomatic therapy is recommended for long COVID, but a specific treatment has not yet been proposed. Recently, morbidity code for post COVID-19 conditions was created, and it is planned to announce guidelines for long COVID treatment and management in the first half of 2023. In line with this trend, the Korean medical community needs to make efforts to prepare treatment guidelines for patients with long COVID.

Abstract

Even after testing negative for COVID-19, some patients continue to struggle with a variety of symptoms such as fatigue, shortness of breath, gastrointestinal problems and neurological problems. The World Health Organization (WHO) defined long COVID (Post COVID-19 conditions) as “A disease occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months, that cannot be explained by an alternative diagnosis.” As a possible pathological mechanism of long COVID, three hypotheses are proposed: the persistence of the infectious state due to the residual virus, the persistent inflammatory response, and the autoimmune response. The main symptoms of long COVID are shortness of breath (dyspnea), abdominal pain and dyspepsia, fatigue, cognitive problems (brain fog), anosmia and dysgeusia, and chest pain, palpitations and tachycardia. In the Chinese guidelines, COVID-19 patients were divided into mild, moderate, severe, and recovery, and prescriptions with effective therapeutic effects were summarized to encourage combined treatment of chinese and western medicine. Globally, only symptomatic therapy is recommended for long COVID, but a specific treatment has not yet been proposed. Recently, morbidity code for post COVID-19 conditions was created, and it is planned to announce guidelines for long COVID treatment and management in the first half of 2023. In line with this trend, the Korean medical community needs to make efforts to prepare treatment guidelines for patients with long COVID.

참고문헌 (54)

  1. "Coronavirus Infectious Disease-19 Outbreak Status" (2022)[URL]
  2. "WHO coronavirus (COVID-19) Dashboard" (2022)[URL]
  3. Anthony King, "An uncommon cold", New Sci, 246(3280), pp.32~35 (2020)
  4. "Human Coronavirus Types" (2020)[URL]
  5. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, "The species Severe acute respiratory syndrome-related coronavirus : classifying 2019-nCoV and naming it SARS-CoV-2", Nat Microbiol, 5(4), pp.536~544 (2020)
  6. Mehandru S, "Pathological sequelae of long-haul COVID", Nat Immunol, 23(2), pp.194~202 (2022)
  7. Nogrady B, "What the data say about asymptomatic COVID infections", Nature, 587(7835), pp.534~535 (2020)
  8. "Corona 19 related permission and approval status - emergency use approval status and corona treatment approval status" (2022)[URL]
  9. Nalbandian A, "Post-acute COVID-19 syndrome", Nat Med, 27(4), pp.601~615 (2021)
  10. Del Rio C, "Long-term health consequences of COVID-19", JAMA, 324, pp.1723~1724 (2020)
  11. Havervall S, "Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers", JAMA, 325(19), pp.2015~2016 (2021)
  12. Tenforde MW, "Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020", MMWR Morb Mortal Wkly Rep, 69(30), pp.993~998 (2020)
  13. Swartz MK, "Post-COVID Conditions in Children", J Pediatr Health Care, 35(5), pp.457~458 (2021)
  14. Al-Aly Z, "High-dimensional characteriza-tion of post-acute sequelae of COVID-19", Nature, 594, pp.259~264 (2021)
  15. "Why we need to keep using the patient made term "Long Covid"" (2020)[URL]
  16. Akbarialiabad H, "Long COVID, a comprehensive systematic scoping review", Infection, 49(6), pp.1163~1186 (2021)
  17. Callan C, "'I can't cope with multiple inputs' : a qualitative study of the lived experience of 'brain fog' after COVID-19", BMJ Open, 12(2), pp.e056366~ (2022)
  18. "Emergency use ICD codes for COVID-19 disease outbreak" (2021)[URL]
  19. "ICD-11 for Mortality and Morbidity Statistics" (2022)[URL]
  20. Soriano JB, "A clinical case definition of post-COVID-19 condition by a Delphi consensus", Lancet Infect Dis, 22(4), pp.e102~e107 (2022)[DOI]
  21. Chen C, "Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review", J Infect Dis, pp.jiac136~ (2022)
  22. 이경은, "코로나-19 환자의 후유증 한약 치료에 대한 고찰", 대한한방내과학회지, 42(1), pp.53~66 (2021), 대한한방내과학회[DOI]
  23. "Clinical practice guideline for COVID-19 ver. 2.1" (2020)[URL]
  24. "Post-COVID Conditions" (2022)[URL]
  25. "COVID-19 rapid guideline: managing the long term effects of COVID-19 - NICE, RCGP, and SIGN" (2021)[URL]
  26. A.V. Raveendran, "Long COVID19:Challenges in the diagnosis and proposed diagnostic criteria", Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15, pp.145~146 (2021)
  27. Livanos AE, "Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms", Gastroenterology, 160(7), pp.2435~2450 (2021)
  28. Wölfel R, "Virological assessment of hospitalized patients with COVID-2019", Nature, 581(7809), pp.465~469 (2020)
  29. Randall RE, "Within host RNA virus persistence : mechanisms and consequences", Curr Opin Virol, 23, pp.35~42 (2017)
  30. Hoeffel G, "C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages", Immunity, 42(4), pp.665~678 (2015)
  31. Bost P, "Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients", Cell, 181(7), pp.1475~1488.e12 (2020)
  32. Hadjadj J, "Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients", Science, 369(6504), pp.718~724 (2020)
  33. Ohashi PS, "Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice", Cell, 65(2), pp.305~317 (1991)
  34. Bergamaschi L, "Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease", Immunity, 54(6), pp.1257~1275.e8 (2021)[DOI]
  35. Wang EY, "Diverse functional autoantibodies in patients with COVID-19", Nature, 595(7866), pp.283~288 (2021)
  36. "Management of Post-COVID Conditions" (2021)[URL]
  37. Yong SJ, "Long COVID or post-COVID-19 syndrome : putative pathophysiology, risk factors, and treatments", Infect Dis (Lond), 53(10), pp.737~754 (2021)
  38. Crook H, "Long covid-mechanisms, risk factors, and management", BMJ, 374, pp.n1648~ (2021)
  39. Gandhi S, "Is the Collapse of the Respiratory Center in the Brain Responsible for Respiratory Breakdown in COVID-19 Patients?", ACS Chem Neurosci, 11(10), pp.1379~1381 (2020)
  40. Mao R, "Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5(7), pp.667~678 (2020)
  41. Meinlschmidt G, "Depressive symptoms, but not anxiety, predict subsequent diagnosis of Coronavirus disease 19 : a national cohort study", Epidemiol Psychiatr Sci, 31, pp.e16~ (2022)
  42. Yonghyun Lee, "Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients", Journal of Korean Medical Science, 35(18), pp.1~6 (2020), 대한의학회[DOI]
  43. Saniasiaya J, "Parosmia post COVID-19: an unpleasant manifestation of long COVID syndrome", Postgrad Med J, 98, pp.e96~ (2022)
  44. "Pneumonia Treatment Plan for COVID-19" (2020)[URL]
  45. "New Coronavirus Pneumonia Treatment Programme" (2022)[URL]
  46. Lin A, "The contribution of herbal medicine to COVID-19 pandemic", Doctor, pp.2022
  47. "Recommendation for Korean medicine treatment for COVID-19" (2020)[URL]
  48. Hong BH, "Suggestions on the Use of Korean and Western Medicine for COVID-19 Treatment", pp.2020
  49. Korean Medicine Basic Education Practice Competency Learning Outcomes, "Kang S", IKMEE, 394~396 (2020)
  50. US Department of Health and Human Services, "Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Putpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020", Morbidity and Mortality Weekly Report, 69(30), pp.993~998 (2020)
  51. "Corona mutation BA.5 has the highest transmission power among viruses that attack humans" (2022)[URL]
  52. Internal Korean Medicine for the pulmonary system, "Chung S", Pulmonary Internal Medicine Council of College of Korean Medicine, 125~137 (2011)
  53. Li Q, "Prolonged shedding of severe acute respiratory syndrome coronavirus 2 in patients with COVID-19", Emerg Microbes Infect, (1), pp.2571~2577 (2020)
  54. interpretation on the Proposal of Syndrome Differentiation for COVID-19 in Traditional Chinese Medicine by TCM Master Zhou Zhong-ying, "Yip F", Lanzhou University, 141~144 (2020)

관련 논문AI추천

한방병원에 내원한 급성기 이후 코로나-19 환자 15명에 대한 임상적 특징 및 치료 분석 : 사례군 연구김관일, 박지원, 신정원, 이범준, 정희재, 홍성은대한한방내과학회 · 대한한방내과학회지2022 · 제43권 제3호코로나-19 환자의 후유증 한약 치료에 대한 고찰송미덕, 이경은, 장인수, 정민정, 정선형, 최유민대한한방내과학회 · 대한한방내과학회지2021 · 제42권 제1호COVID-19 감염 후유증 환자에 대한 한의복합치료 2례 보고김선중, 박현서, 서주희, 윤인애, 하지수대한한방내과학회 · 대한한방내과학회지2023 · 제44권 제5호만성 코로나19증후군 진단 및 치료의 최신 지견김탁, 김성은, 김윤정, 김은정, 김태화, 서유빈, 서준원, 송준영, 이소희, 이은정, 이재갑, 정영훈, 정영희, 최유정대한내과학회 · 대한내과학회지2025 · 제100권 제2호『傷寒論』 辨病 診斷體系에 근거하여 生薑瀉心湯 투여 후 호전된 피로를 주소로 하는 Post-COVID-19 Syndrome 1례김상호, 서영호, 최해윤, 황보민대한상한금궤의학회 · 대한상한금궤의학회지2022 · 제14권 제1호COVID-19 후유증으로 기능성 소화불량이 악화된 환자에 대한 한의치험 1례권태하, 노정희, 박무진, 설동수, 송우섭, 신주연, 오은제, 오주희, 이승희, 이윤정, 장동진대한한방내과학회 · 대한한방내과학회지2023 · 제44권 제5호

이 간행물의 다른 논문 (7건)

전염성 감염병에 대한 신속변증 시행을 위한 팔강복합증형 표준안 연구지규용pp. 147-154COVID-19 중국 진료방안의 변증론치에 대한 고찰김상현pp. 163-168한의학 腎 기능계에 관한 분자생리학적 고찰조정효, 유호룡, 박미소, 허왕정pp. 169-174과루인 에탄올 추출물의 혈관신생 억제효과박현지, 박신형pp. 175-180백출과 양춘사 추출 혼합물의 항콜레스테롤 효과 및 기전 연구권강범, 정현종, 김예슬, 김하림pp. 181-186
원문 보기